Systemic Therapy for Previously Treated Advanced Gastric Cancer: A Systematic Review and Network Meta-Analysis

2018 ◽  
Author(s):  
Ji Cheng ◽  
Ming Cai ◽  
Xiaoming Shuai ◽  
Jinbo Gao ◽  
Guobin Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systematic Review ◽  
Advanced Gastric Cancer ◽  
Systemic Therapy ◽  
Meta Analysis ◽  
Previously Treated

scholarly journals The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis

2016 ◽  
Vol 19 (3) ◽  
pp. 696-712 ◽  
Author(s):  
Emil ter Veer ◽  
Nadia Haj Mohammad ◽  
Paul Lodder ◽  
Lok Lam Ngai ◽  
Mary Samaan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systematic Review ◽  
Advanced Gastric Cancer ◽  
Meta Analysis ◽  
Line Treatment ◽  
Efficacy And Safety ◽  
First Line ◽  
First Line Treatment

scholarly journals Oncologic value of laparoscopy-assisted distal gastrectomy for advanced gastric cancer: A systematic review and meta-analysis

2016 ◽  
Vol 12 (3) ◽  
pp. 199 ◽  
Author(s):  
Andrea Sagnotta ◽  
Paolo Aurello ◽  
Irene Terrenato ◽  
Giammauro Berardi ◽  
Giuseppe Nigri ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systematic Review ◽  
Advanced Gastric Cancer ◽  
Distal Gastrectomy ◽  
Meta Analysis

A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for advanced gastric cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4614-4614 ◽  
Author(s):  
T. D. Yan ◽  
D. Black ◽  
P. H. Sugarbaker ◽  
Y. Yonemura ◽  
J. Zhu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Systematic Review ◽  
Overall Survival ◽  
Advanced Gastric Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Data Extraction ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Abdominal Abscess ◽  
Term Survival

4614 Objectives: Despite the use of adjuvant systemic chemotherapy or radiotherapy, the long-term survival in patients with stage III and IV gastric cancer remains limited. The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with advanced gastric cancer. Methods: Studies eligible for this systematic review included those in which patients with gastric cancer were randomly assigned to receive surgery combined with intraperitoneal chemotherapy versus surgery without intraperitoneal chemotherapy. All forms of intraperitoneal chemotherapy in addition to surgery were included. There were no language restrictions. Quality of the trials was assessed by a predetermined checklist. The primary end-point of the meta-analysis was overall survival, defined as the time from random assignment to the last follow-up or death. Secondary end-points were the differences in the incidence of recurrence, morbidity and mortality. Results: Thirteen reports of randomised controlled trials (RCTs) were included for appraisal and data extraction. Ten reports were judged fair-quality and subjected to the meta-analysis. A significant improvement in survival was associated with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) alone (HR = 0.60; 95% CI = 0.43 to 0.83; p = 0.002) or combined with early postoperative intraperitoneal chemotherapy (EPIC) (HR = 0.45; 95% CI = 0.29 to 0.68; p = 0.0002). Survival improvement was marginally significant (HR = 0.67; 95% CI = 0.44 to 1.01; p = 0.06) with normothermic intraoperative intraperitoneal chemotherapy, but not significant with EPIC alone or delayed postoperative intraperitoneal chemotherapy. Intraperitoneal chemotherapy was also found to be associated with higher risks for intra-abdominal abscess (RR = 2.37; 95% CI = 1.32 to 4.26; p = 0.003) and neutropenia (RR = 4.33; 95% CI = 1.49 to 12.61; p = 0.007). Conclusion: The present meta-analysis indicates that HIIC with or without EPIC after resection of advanced gastric primary cancer is associated with an improved overall survival. However, increased risks of intra-abdominal abscess and neutropenia are demonstrated. No significant financial relationships to disclose.

scholarly journals Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis

Medicine ◽  
2016 ◽  
Vol 95 (24) ◽  
pp. e3916 ◽  
Author(s):  
Xiao-Dong Chen ◽  
Fu-Qian He ◽  
Mi Chen ◽  
Ling-Chao Tang ◽  
Xiao-Li Tang
Keyword(s):  
Gastric Cancer ◽  
Systematic Review ◽  
Advanced Gastric Cancer ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document